Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...

WuXi Biologics employees have once again exemplified their deep-rooted commitment to the local community, delivering ...

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Speaking with Stat ahead of his exit, Robert Califf expressed concern about the potential for brain drain in government. Other news is on promising drugs for lung cancer patients, the upcoming J.P.

WuXi Biologics grants exclusive global rights of trispecific t-cell engager to Candid Therapeutics: Shanghai Wednesday, January 8, 2025, 15:00 Hrs [IST] WuXi Biologics, a leading ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co.

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

Current health news includes Trump considering protective measures for gas appliances against regulatory changes. The WHO ...

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...

WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...